Andras Inotai PharmD PhD
Andras Inotai PharmD PhD
Institute Economics, Faculty of Social Sciences, Eötvös Loránd University, Budapest
Підтверджена електронна адреса в
Factors associated with medication adherence in patients with chronic obstructive pulmonary disease
T Agh, A Inotai, A Meszaros
Respiration 82 (4), 328-334, 2011
Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review
T Agh, G Kovács, M Pawaskar, D Supina, A Inotai, Z Vokó
Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity 20 (1 …, 2015
Trends in the non‐steroidal anti‐inflammatory drug market in six Central–Eastern European countries based on retail information
A Inotai, B Hankó, Á Mészáros
Pharmacoepidemiology and drug safety 19 (2), 183-190, 2010
Relationship between medication adherence and health-related quality of life in subjects with COPD: a systematic review
T Ágh, P Dömötör, Z Bártfai, A Inotai, E Fujsz, Á Mészáros
Respiratory care 60 (2), 297-303, 2015
Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries
T Bochenek, V Abilova, A Alkan, B Asanin, I de Miguel Beriain, Z Besovic, ...
Frontiers in pharmacology 8, 942, 2018
Is there a reason for concern or is it just hype?–A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
A Inotai, CPJ Prins, M Csanadi, D Vitezic, C Codreanu, Z Kalo
Expert opinion on biological therapy 17 (8), 915-926, 2017
Need for multicriteria evaluation of generic drug policies
Z Kaló, AP Holtorf, R Alfonso-Cristancho, J Shen, T Ágh, A Inotai, ...
Value in health 18 (2), 346-351, 2015
Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology
A Inotai, M Pékli, G Jóna, O Nagy, E Remák, Z Kaló
BMC health services research 12 (1), 332, 2012
Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis
A Inotai, B Rojkovich, A Fülöp, E Jászay, T Ágh, Á Mészáros
Rheumatology international 32 (4), 963-969, 2012
Pharmaceutical regulation in Central and Eastern European countries: a current review
P Kawalec, T Tesar, L Vostalova, P Draganic, M Manova, A Savova, ...
Frontiers in pharmacology 8, 892, 2017
Guidance toward the implementation of multicriteria decision analysis framework in developing countries
A Inotai, HT Nguyen, B Hidayat, T Nurgozhin, PHT Kiet, JD Campbell, ...
Expert review of pharmacoeconomics & outcomes research 18 (6), 585-592, 2018
Modelling the burden of disease associated malnutrition
A Inotai, M Nuijten, E Roth, R Hegazi, Z Kaló
e-SPEN Journal 7 (5), e196-e204, 2012
Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts
A Inotai, M Csanadi, G Petrova, M Dimitrova, T Bochenek, T Tesar, K York, ...
BioMed research international 2018, 2018
Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low-and middle-income countries
B Németh, A Molnár, S Bozóki, K Wijaya, A Inotai, JD Campbell, Z Kaló
Journal of comparative effectiveness research 8 (4), 195-204, 2019
Policy practices to maximise social benefit from biosimilars
A Inotai, M Csanádi, D Vitezic, I Francetic, T Tesar, T Bochenek, ...
Journal of Bioequivalence & Bioavailability 9 (4), 467-472, 2017
Benefits of investment into modern medicines in Central–Eastern European countries
A Inotai, G Petrova, D Vitezic, Z Kalo
Expert Review of Pharmacoeconomics & Outcomes Research 14 (1), 71-79, 2014
Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals–an application on improving tender decision making in Indonesia
A Inotai, D Brixner, N Maniadakis, I Dwiprahasto, E Kristin, A Prabowo, ...
BMC health services research 18 (1), 1003, 2018
Osteoporotic fractures may impair life as much as the complications of diabetes
Z Vokó, K Gáspár, A Inotai, C Horváth, K Bors, G Speer, Z Kaló
Journal of evaluation in clinical practice 23 (6), 1375-1380, 2017
Managing the introduction of new and high-cost drugs in challenging times: the experience of Hungary and Poland
D Kwong, A Ferrario, J Adamski, A Inotai, Z Kaló
EuroHealth 20 (2), 25-28, 2014
Implications of economic crisis on health care decision-making in Hungary: An opportunity to change
Z Kaló, I Boncz, A Inotai
Journal of Health Policy and Outcomes Research 1, 20-26, 2012
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20